Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2021-06-30 Capital/Financing Update
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 30, 2021, reporting a current event: a five-year research collaboration agreement between Apellis Pharmaceuticals and Beam Therapeutics. The content focuses on the terms of the collaboration, milestone payments, and forward-looking statements. There are no financial statements or detailed financial performance data presented. The document is an announcement of a material event related to the company's business activities, specifically a collaboration and financing milestone payments. This fits the category of Capital/Financing Update (CAP), as it involves funding and collaboration agreements with milestone payments. It is not an Annual Report, Earnings Release, or other report types. The length is about 5934 characters, sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2021-06-30 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-29 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-26 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-22 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.